COMPANY PROFILE

NantCell | Nantworks

Explore full profile

Developing knowledge by harnessing the power of the immune system to treat cancer

Culver City, United StatesFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2014
Headquarters: Culver City, United States
Employees: 68
Open positions: None listed
Dealroom signal: 40.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Molecular, Biotech and Pharma, DT and LS, science-based
Technology: Hardware
Business model: Manufacturing
Client focus: b2b, b2c
Investment activity: 13 companies, latest Feb 2026
Capital deployed: $355M
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2018	$30M	$120M	Undisclosed	—
GROWTH EQUITY VCOther financing	Jan 2016	$57M	$399M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

NantCell | Nantworks website traffic

Latest recorded traffic for NantCell | Nantworks is 340 monthly website visits, down 85.8% over the last three months. NantCell | Nantworks's team grew 0% over the past year.

Latest monthly visits340 3-month web change-85.8% 1-year team growth0%

Monthly website visitsSep 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FMFoundation MedicineTransformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease	Boston, United States	Acquired	1,762	$97M	$5.3B
IBImmatics biotechnologiesCombines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets	Tübingen, Germany	Operational
PRProteaProtea is a commercial stage molecular information company, leading in the field of mass spectrometey imaging. http://t.co/Jy8X3awz9r	Morgantown, United States	Operational
BIBiodesixA molecular diagnostics company at the forefront of innovation in oncology	Boulder, United States	Operational
NANanobiotixNanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell	Paris, France	Operational
IBInnovent BiologicsInnovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies	Suzhou Shi, China	Operational
RBRedHill BiopharmaRedHill (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on proprietary drugs for gastrointestinal diseases	Raleigh, United States	Operational
CPConvert PharmaceuticalsHypoxia-activated prodrugs targeting treatment-resistant tumors	Liège, Belgium	Operational